Middle life years


 

More and more multiple sclerosis (MS) patients seen in clinical practice are middle-aged or older [1-4]. With age, vulnerability may increase, especially when other factors such as co-morbidities, obesity or smoking come into play [1,5,6]. Many patients with MS fall into one of these categories, but their special needs are often disregarded [7,8].

 

 

The MS population is ageing

Insights into ageing processes

Insights into the disease course of MS patients when they age

Betaferon in mid-life or older patients with MS


 

MS in middle life years

Viewpoints from experts from around the world

References

  • Vaughn CB et al. Nat Rev Neurol 2019; 15(6): 329-42. Return to content
  • Daltrozzo T et al. Front Neurol 2018; 9: 871. Return to content
  • UK Government. MS data briefing, February 2020. Available at: https://www.gov.uk/government/publications/multiple-sclerosis-prevalence-incidence-and-smoking-status (Last access August 18, 2021). Return to content
  • Wallin MT et al. Neurology 2019; 92(10): e1029-40. Return to content
  • Marrie RA et al. Nat Rev Neurol 2017; 13: 375-82. Return to content
  • Karnoe A et al. Disabil Rehab 2020; 42(24) : 3504-15. Return to content
  • Musella A et al. Front Aging Neurosci 2018; 10: 238. Return to content
  • Jakimovski et al. Exp Rev Neurother 2019; 19: 445-8. Return to content
Alt tag